SELLAS’ cancer programs target diverse indications in hematological cancers and solid tumors.

learn more


The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute as a top priority target for immunotherapy.

learn more


SELLAS’ therapies have the potential to treat 20+ cancers characterized by an overexpression of the WT1 antigen.

learn more

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Learn More

Latest News

Our Partnerships

SELLAS has an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center for its proprietary WT1 cancer immunotherapy, as well as partnerships with PolyPeptide Group and Corden Pharma.